Compositions and methods for treating rotator cuff injuries
View Patent ↗The present invention provides compositions and methods for attaching tendon to bone. The present invention provides compositions and methods for treating rotator cuff injuries. In one embodiment, a method for treating rotator cuff injuries comprises providing a composition comprising PDGF disposed in a biocompatible matrix and applying the composition to at least one site of tendon reattachment on the humeral head.
1. A method of treating a damaged or injured tendon in an individual comprising:
a) providing a composition consisting of a PDGF solution disposed in a biocompatible matrix,
wherein the biocompatible matrix is selected from the group consisting of: a biocompatible matrix consisting of collagen, and a biocompatible matrix consisting of collagen and a polysaccharide,
wherein the PDGF solution consists of PDGF in a buffer,
wherein the PDGF solution has a concentration of PDGF of about 0.05 mg/ml to about 5 mg/ml, and
wherein the biocompatible matrix has a porosity greater than about 25%, and
b) applying the composition in vivo to the damaged or injured tendon.
2. The method of claim 1 , wherein the at least one tendon has tearing, delamination, strain, deformation, or combinations thereof.
3. The method of claim 1 , wherein the method is a method for attaching the tendon to a bone, and wherein the composition is applied to at least one site of tendon attachment on the bone.
4. The method of claim 3 , wherein the method comprises treating a rotator cuff tear, wherein the bone is a humeral head.
5. The method of claim 4 , wherein the at least one site of tendon attachment comprises a channel in cortical bone of the humeral head.
6. The method of claim 5 , wherein the channel comprises a size and a shape that corresponds to a tendon attachment footprint.
7. The method of claim 4 , further comprising disposing at least one bone anchor in the humeral head and coupling at least one detached tendon to the bone anchor.
8. The method of claim 7 , wherein the at least one bone anchor comprises PDGF and a second biocompatible matrix.
9. The method of claim 7 , wherein the at least one tendon is coupled to the at least one bone anchor through at least one suture.
10. The method of claim 9 , wherein the at least one suture is coated with PDGF.
11. The method of claim 7 , wherein the composition is positioned between the humeral head and the tendon.
12. The method of claim 4 , further comprising molding the composition to contours of the tendon attachment site.
13. The method of claim 4 , wherein applying the composition comprises injecting the composition at the tendon reattachment site.
14. The method of claim 1 , wherein the method is a method of strengthening the attachment of the tendon to a bone, and wherein the composition is applied to a site of tendon attachment to the bone.
15. The method of claim 1 , wherein the biocompatible matrix consists of collagen.
16. The method of claim 15 , wherein the biocompatible matrix is a collagen patch or pad.
17. The method of claim 15 , wherein the composition is flowable.
18. The method of claim 15 , wherein the PDGF solution has a concentration of PDGF ranging from about 0.1 mg/ml to about 1.0 mg/ml.
19. The method of claim 15 , wherein the PDGF solution has a concentration of PDGF ranging from about 0.1 mg/ml to about 0.3 mg/ml.
20. The method of claim 15 , wherein the PDGF solution has a concentration of PDGF of about 0.15 mg/ml.
21. The method of claim 15 , wherein the PDGF solution has a concentration of PDGF of about 0.3 mg/ml.
22. The method of claim 15 , wherein the PDGF solution consists of PDGF in a sodium acetate buffer.
23. The method of claim 15 , wherein the PDGF is rhPDGF-BB.
24. The method of claim 15 , wherein the biocompatible matrix has a porosity greater than about 50%.
25. The method of claim 15 , wherein the biocompatible matrix has a porosity greater than about 90%.
26. The method of claim 15 , wherein the biocompatible matrix is resorbed within 1 month of in vivo application.
27. The method of claim 15 , wherein the biocompatible matrix provides a framework suitable for bone and tendon tissue in-growth.
28. The method of claim 15 , wherein the biocompatible matrix is a collagen pad or patch, wherein the PDGF solution has a concentration of PDGF ranging from about 0.1 mg/ml to about 1.0 mg/ml, and wherein the biocompatible matrix has a porosity greater than about 50%.
29. The method of claim 28 , wherein the method is a method for attaching the tendon to a bone, and wherein the composition is applied to at least one site of tendon attachment on the bone.
30. The method of claim 15 , wherein the biocompatible matrix is a collagen pad or patch, wherein the PDGF solution has a concentration of PDGF ranging from about 0.1 mg/ml to about 0.3 mg/ml, wherein the PDGF solution consists of PDGF in a sodium acetate buffer, wherein the biocompatible matrix has a porosity greater than about 50%, and wherein the biocompatible matrix is resorbed within 1 month of in vivo application.
31. The method of claim 15 , wherein the at least one tendon has tearing, delamination, strain, deformation, or combinations thereof.
32. The method of claim 15 , wherein the method is a method for attaching the tendon to a bone, and wherein the composition is applied to at least one site of tendon attachment on the bone.
33. The method of claim 15 , wherein the method is a method of strengthening the attachment of the tendon to a bone, and wherein the composition is applied to a site of tendon attachment to the bone.
34. The method of claim 15 , wherein the biocompatible matrix is resorbed with 3 months of in vivo application.
35. The method of claim 15 , wherein the PDGF is recombinant human PDGF.
36. The method of claim 15 , wherein the PDGF is PDGF-BB.
37. The method of claim 15 , wherein the collagen is type I collagen.